HUP9802651A2 - Oltóanyagok részecskék célba juttatásával végzett genetikai immunizálással kiváltott, sejtközvetített immunválasz stimulálására - Google Patents
Oltóanyagok részecskék célba juttatásával végzett genetikai immunizálással kiváltott, sejtközvetített immunválasz stimulálásáraInfo
- Publication number
- HUP9802651A2 HUP9802651A2 HU9802651A HUP9802651A HUP9802651A2 HU P9802651 A2 HUP9802651 A2 HU P9802651A2 HU 9802651 A HU9802651 A HU 9802651A HU P9802651 A HUP9802651 A HU P9802651A HU P9802651 A2 HUP9802651 A2 HU P9802651A2
- Authority
- HU
- Hungary
- Prior art keywords
- antigen
- genetic immunization
- stimulation
- cell
- immune responses
- Prior art date
Links
- 230000002068 genetic effect Effects 0.000 title abstract 2
- 230000003053 immunization Effects 0.000 title abstract 2
- 238000002649 immunization Methods 0.000 title abstract 2
- 230000021633 leukocyte mediated immunity Effects 0.000 title 1
- 230000000638 stimulation Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 210000004027 cell Anatomy 0.000 abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 210000000805 cytoplasm Anatomy 0.000 abstract 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000000612 antigen-presenting cell Anatomy 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
- A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001186—MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Developmental Biology & Embryology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A találmány szerinti megőldás emlősben (az embert is beleértve)antigén-specifikűs imműnválasz stiműlálására alkalmas genetikaiimműnizálásra vőnatkőzik. A leírásban szemcsés főrmájú pőlinűkleőtidőkgazdasejtek, példáűl antigénbeműtató sejtek citőplazmájába történőcélba jűttatását ismerteti. Ezek a szemcsés főrmájú plinűkleőtidőkantigén tűlajdőnságú fehérjét vagy antigén tűlajdőnságúfehérjefragmenst kódőlnak, amely bejűt a célsejt citőplazmájába. Azantigén génjének espressziója antigén-specifikűs imműnválaszt, példáűlantigén-specifi-kűs citőtőxikűs T-limfőciták (CTL-ek) indűkálásáteredményezi, amelyek elpűsztítják a kárősődőtt sejteket, példáűldaganatős vagy vírűsfertőzött sejteket. ŕ
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US53555695A | 1995-09-28 | 1995-09-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP9802651A2 true HUP9802651A2 (hu) | 1999-02-01 |
HUP9802651A3 HUP9802651A3 (en) | 2001-08-28 |
Family
ID=24134735
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU9802651A HUP9802651A3 (en) | 1995-09-28 | 1996-09-27 | Stimulation of cell-mediated immune responses by targeted particulate genetic immunization |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0863704A4 (hu) |
JP (1) | JPH11512724A (hu) |
KR (1) | KR19990063672A (hu) |
CN (1) | CN1201369A (hu) |
AU (1) | AU716497B2 (hu) |
BG (1) | BG102355A (hu) |
CA (1) | CA2233278A1 (hu) |
CZ (1) | CZ92998A3 (hu) |
HU (1) | HUP9802651A3 (hu) |
NO (1) | NO981386L (hu) |
NZ (1) | NZ319891A (hu) |
PL (1) | PL325953A1 (hu) |
SK (1) | SK40198A3 (hu) |
TR (1) | TR199800573T2 (hu) |
WO (1) | WO1997011605A1 (hu) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6110898A (en) * | 1996-05-24 | 2000-08-29 | University Of Maryland, Baltimore | DNA vaccines for eliciting a mucosal immune response |
TW570803B (en) * | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
US6287569B1 (en) * | 1997-04-10 | 2001-09-11 | The Regents Of The University Of California | Vaccines with enhanced intracellular processing |
AU3291099A (en) * | 1998-02-11 | 1999-08-30 | Maxygen, Inc. | Genetic vaccine vector engineering |
CA2358385C (en) | 1998-12-31 | 2013-08-06 | Chiron Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
JP2002542264A (ja) * | 1999-04-21 | 2002-12-10 | パウダージェクト ヴァクシンズ,インコーポレイテッド | 核酸による免疫化 |
EP1372704B1 (en) * | 2001-03-30 | 2008-10-15 | Ghc Research Development Corporation | Monocyte-specific particulate delivery vehicle |
WO2003004620A2 (en) | 2001-07-05 | 2003-01-16 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
US11529414B2 (en) | 2020-06-23 | 2022-12-20 | Orbis Health Solutions, Llc | Viral vaccines for in vivo expression of a nucleic acid encoding an immunogenic peptide and methods of using the same |
-
1996
- 1996-09-27 PL PL96325953A patent/PL325953A1/xx unknown
- 1996-09-27 NZ NZ319891A patent/NZ319891A/xx unknown
- 1996-09-27 HU HU9802651A patent/HUP9802651A3/hu unknown
- 1996-09-27 CN CN96198106A patent/CN1201369A/zh active Pending
- 1996-09-27 WO PCT/US1996/015728 patent/WO1997011605A1/en not_active Application Discontinuation
- 1996-09-27 SK SK401-98A patent/SK40198A3/sk unknown
- 1996-09-27 EP EP96933987A patent/EP0863704A4/en not_active Withdrawn
- 1996-09-27 CA CA002233278A patent/CA2233278A1/en not_active Abandoned
- 1996-09-27 KR KR1019980702134A patent/KR19990063672A/ko not_active Application Discontinuation
- 1996-09-27 CZ CZ98929A patent/CZ92998A3/cs unknown
- 1996-09-27 AU AU72515/96A patent/AU716497B2/en not_active Ceased
- 1996-09-27 TR TR1998/00573T patent/TR199800573T2/xx unknown
- 1996-09-27 JP JP9513762A patent/JPH11512724A/ja active Pending
-
1998
- 1998-03-26 NO NO981386A patent/NO981386L/no unknown
- 1998-03-26 BG BG102355A patent/BG102355A/xx unknown
Also Published As
Publication number | Publication date |
---|---|
PL325953A1 (en) | 1998-08-17 |
HUP9802651A3 (en) | 2001-08-28 |
CZ92998A3 (cs) | 1998-09-16 |
NZ319891A (en) | 1999-01-28 |
KR19990063672A (ko) | 1999-07-26 |
NO981386L (no) | 1998-05-28 |
AU7251596A (en) | 1997-04-17 |
EP0863704A1 (en) | 1998-09-16 |
WO1997011605A1 (en) | 1997-04-03 |
TR199800573T2 (xx) | 1998-07-21 |
JPH11512724A (ja) | 1999-11-02 |
BG102355A (en) | 1999-04-30 |
NO981386D0 (no) | 1998-03-26 |
EP0863704A4 (en) | 2003-09-10 |
CA2233278A1 (en) | 1997-04-03 |
AU716497B2 (en) | 2000-02-24 |
SK40198A3 (en) | 1998-11-04 |
CN1201369A (zh) | 1998-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Le Bon et al. | Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon | |
Staveley-O’Carroll et al. | Induction of antigen-specific T cell anergy: an early event in the course of tumor progression | |
Basham et al. | Recombinant interferon-gamma increases HLA-DR synthesis and expression. | |
Mattei et al. | IL-15 is expressed by dendritic cells in response to type I IFN, double-stranded RNA, or lipopolysaccharide and promotes dendritic cell activation | |
Irvine et al. | Efficient nonviral transfection of dendritic cells and their use for in vivo immunization | |
Hui et al. | Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation | |
Shi et al. | Cell death releases endogenous adjuvants that selectively enhance immune surveillance of particulate antigens | |
Pampena et al. | Natural killer cells as helper cells in dendritic cell cancer vaccines | |
HUP0004611A2 (hu) | APRIL, egy új növekedési hatású fehérje | |
GR3031026T3 (en) | Lysosomal targeting of immunogens. | |
ZA988124B (en) | Mage-3 peptides presented by HLA class II molecules | |
DE69924826T8 (de) | Verwendung vom krebs-assoziierten antigen 5t4 zur immuntherapie | |
HUP9802651A2 (hu) | Oltóanyagok részecskék célba juttatásával végzett genetikai immunizálással kiváltott, sejtközvetített immunválasz stimulálására | |
Streit et al. | Protective immunity against the protozoan Leishmania chagasi is induced by subclinical cutaneous infection with virulent but not avirulent organisms | |
Ohata et al. | Enhanced efficacy of regulatory T cell transfer against increasing resistance, by elevated Foxp3 expression induced in arthritic murine hosts | |
Wang et al. | Prime–boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice | |
US20120045477A1 (en) | Method for Treating Cancer with Toxoplasma Gondii Vaccine | |
Kuczma et al. | Intratumoral convergence of the TCR repertoires of effector and Foxp3+ CD4+ T cells | |
DK0843731T3 (da) | Adenovirusvektorer til genterapi | |
Griffith et al. | Inhibition of murine prostate tumor growth and activation of immunoregulatory cells with recombinant canarypox viruses | |
Staege et al. | Functional and molecular characterization of interleukin‐2 transgenic Ewing tumor cells for in vivo immunotherapy | |
Delman et al. | Efficacy of multiagent herpes simplex virus amplicon-mediated immunotherapy as adjuvant treatment for experimental hepatic cancer | |
Dezfouli et al. | Enhancing CTL responses to melanoma cell vaccines in vivo: synergistic increases obtained using IFNγ primed and IFNβ treated B7‐1+ B16‐F10 melanoma cells | |
Xu et al. | Genetic modulation of tumor antigen presentation | |
Suzuki et al. | IFN-γ production by brain-resident cells activates cerebral mRNA expression of a wide spectrum of molecules critical for both innate and T cell-mediated protective immunity to control reactivation of chronic infection with Toxoplasma gondii |